STIC Search Report
Biotech-Chem Library

STIC Database Tracking Number: 191297

TO: Shirley Gembeh
Location: rem/3A44/3C70
Art Unit: 1614
Tuesday, May 30, 2006

Case Serial Number: 10/743354

From: Deirdre Arnold
Location: Biotech-Chem Library
REM 1A55
Phone: 571-272-2532

Deirdre.Arnold@uspto.gov

Search Notes

RUSH

- Please check the structure for accuracy.
- In accordance with your request, only the elected species (circled) was searched. There were very few hits. ***If you would like to broaden the search by making the structure less defined, please contact me.***
- Beware of false hits on the names in the inventor search.

Please feel free to contact me if you have any questions or would like to amend the search.

Thank you for using STIC services.

Regards,
Deirdre Arnold

ACCESS DB # 191297

FOR OFFICIAL USE ONLY *PLEASE PRINT CLEARLY*

RECEIVED
MAY 30 2006
SCIENTIFIC INFO...

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Gembeh S Examiner # : 80889 Date: 5/30/06
Art Unit: 1614 Phone Number: 2-3504 Serial Number: 10,743,354
Location (Bldg/Room#): Rem 3A44 (Mailbox #): 3C70 Results Format Preferred (circle): PAPER DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

MG

Title of Invention: Heteroarylalkanoic acids as integrin recepter

Inventors (please provide full names): Boys et al

Earliest Priority Date: 12/20/02

Search Topic:
Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search elected compound (cycled cmp)
(see attachment in Applicants response)
Thank you. (ASAP if possible)

Result Search approved Christopher bw 30 May 2006

****

STAFF USE ONLY

Searcher: _____
Searcher Phone #: _____
Searcher Location: _____
Date Searcher Picked Up: _____
Date Completed: _____
Searcher Prep & Review Time: _____
Online Time: _____

Type of Search

_____ NA Sequence (#)
_____ AA Sequence (#)
_____ Structure (#)
_____ Bibliographic
_____ Litigation
_____ Fulltext
_____ Other

Vendors and cost where applicable

_____ STN _____ Dialog
_____ Questel/Orbit _____ Lexis/Nexis
_____ Westlaw _____ WWW/Internet
____ In-house sequence systems
__ Commercial ___ Oligomer ____ Score/Length
__ Interference ___ SPDI ____ Encode/Transl
_____ Other (specify)

STIC SEARCH RESULTS FEEDBACK FORM

USPTO

Biotech-Chem Library

Questions about the scope or the results of the search? Contact *the searcher or contact*:

Mary Hale, Information Branch Supervisor
571-272-2507 Remsen E01 D86

Voluntary Results Feedback Form

- *I am an examiner in Workgroup:* ☐ *Example: 1610*
- *Relevant prior art **found**, search results used as follows:*
  - ☐ 102 rejection
  - ☐ 103 rejection
  - ☐ Cited as being of interest.
  - ☐ Helped examiner better understand the invention.
  - ☐ Helped examiner better understand the state of the art in their technology.

Types of relevant prior art found:

- ☐ Foreign Patent(s)
- ☐ Non-Patent Literature
  (journal articles, conference proceedings, new product announcements etc.)

- *Relevant prior art **not found**:*
  - ☐ Results verified the lack of relevant prior art (helped determine patentability).
  - ☐ Results were not useful in determining patentability or understanding the invention.

Comments:

Drop off or send completed forms to STIC/Biotech-Chem Library, Remsen Bldg.

sira
Search and Information Resources Administration

What is claimed is:

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound selected from the group consisting of:
3-(3,5-ditert-butylphenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid (TFA salt);
3-(3-tert-butyl-5-iodophenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid;
3-(3-tert-butyl-5-bromophenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid;
3-(5-tert-Butyl-2-hydroxyphenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid;
3-[3,5-Ditert-butyl-2-(carboxymethoxy)phenyl]-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid;
3-(5-tert-Butyl-2-methoxyphenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid;
3-(3,5-Ditert-butyl-4-methoxyphenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid;
3-{3-tert-Butyl-5-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-phenyl}-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid;
3-(3,4-Dichlorophenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid trifluoroacetate;
3-(3-Fluoro-4-methylphenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid hydrochloride;
3-(4-Phenoxyphenyl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid trifluoroacetate;
3-(1-Benzofuran-2-yl)-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid trifluoroacetate;
3-[4-(Benzyloxy)phenyl]-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid trifluoroacetate;
3-[4-(Methylsulfonyl)phenyl]-4-{3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}butanoic acid trifluoroacetate;
4-{3-[3-(5,6,7,8-Tetrahydro-1,8-naphthyridin-2-yl)propyl]-1,2,4-oxadiazol-5-yl}-3-[4-(trifluoromethoxy)phenyl]butanoic acid trifluoroacetate;

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

Bib Data Sheet

CONFIRMATION NO. 9317

SERIAL NUMBER	FILING OR 371(c) DATE	CLASS	GROUP ART UNIT	ATTORNEY DOCKET NO.
10/743,354	12/22/2003 RULE	514	1614	PC31766A

APPLICANTS

Mark L. Boys, Brighton, MI;
Lori A. Schretzman, East Hanover, NJ;
Michael B. Tollefson, Dardenne Prairie, MO;
Nizal Samuel Chandrakumar, Grafton, MA;
Ish Kumar Khanna, Libertyville, IL;
Maria Nguyen, Ann Arbor, MI;
Victoria L. Downs, Pinckney, MI;
Scott B. Mohler, Chicago, IL;
Glen J. Gesicki, Chicago, IL;
Thomas D. Penning, Elmhurst, IL;
Barbara B. Chen, Glenview, IL;
Yaping Wang, Acton, MA;
Albert Khilevich, Buffalo Grove, IL;
Bipinchandra N. Desai, Vernon Hills, IL;
Yi Yu, Glenview, IL;
John A. Wendt, South Lyon, MI;
Heather Stenmark, Chicago, IL;
Hongwei Wu, Buffalo Grove, IL;
Renee M. Huff, Park Ridge, IL;
Srinivasan Raj Nagarajan, Chesterfield, MO;
Balekudru Devadas, Chesterfield, MO;
Hwang-Fun Lu, Ballwin, MO;
Mark Russell, Gurnee, IL;
Dale P. Spangler, San Diego, CA;
Mihir D. Parikh, Chesterfield, MO;

**** CONTINUING DATA ***************************

This appln claims benefit of 60/435,467 12/20/2002

**** FOREIGN APPLICATIONS *********************

IF REQUIRED, FOREIGN FILING LICENSE GRANTED
** 04/02/2004

Foreign Priority claimed	STATE OR COUNTRY	SHEETS DRAWING	TOTAL CLAIMS	INDEPENDENT CLAIMS
☐ yes ☐ no	MI	0	5	1
35 USC 119 (a-d) conditions met ☐ yes ☐ no ☐ Met after Allowance				
Verified and Acknowledged Examiner's Signature Initials				

ADDRESS
28940

TITLE

Heteroarylalkanoic acids as integrin receptor antagonists derivatives

```
=> d que stat l9
L1             1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2003-743354/APPS
L3               TRANSFER  PLU=ON  L1 1- RN  :      387 TERMS
L4           387 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3
L5           131 SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND ?NAPHTHYRIDIN?/CNS
L9             1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 AND I/ELS


=> d ide l9
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y



L9   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   724770-27-8  REGISTRY
ED   Entered STN:  10 Aug 2004
CN   1,2,4-Oxadiazole-5-butanoic acid, β-[3-(1,1-dimethylethyl)-5-
     iodophenyl]-3-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]-
     (9CI)  (CA INDEX NAME)
FS   3D CONCORD
MF   C27 H33 I N4 O3
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

              1 REFERENCES IN FILE CA (1907 TO DATE)
              1 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

```
=> => d que stat l16
L14          .     STR
```



```
Page 1-A
11

Page 1-B
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  35

STEREO ATTRIBUTES: NONE
L16           1 SEA FILE=REGISTRY SSS FUL L14

100.0% PROCESSED       3 ITERATIONS                          1 ANSWERS
SEARCH TIME: 00.00.01


=> d que nos l17
L1            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2003-743354/APPS
L3              TRANSFER  PLU=ON  L1 1- RN  :     387 TERMS
L4          387 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3
L5          131 SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND ?NAPHTHYRIDIN?/CNS
L9            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 AND I/ELS
L14             STR
L16           1 SEA FILE=REGISTRY SSS FUL L14
L17           0 SEA FILE=REGISTRY ABB=ON  PLU=ON  L16 NOT L9


=> d que nos l24
L1            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2003-743354/APPS
L3              TRANSFER  PLU=ON  L1 1- RN  :     387 TERMS
L4          387 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3
L5          131 SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND ?NAPHTHYRIDIN?/CNS
L9            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 AND I/ELS
L23           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  724770-27-8/RN,CRN
L24           0 SEA FILE=REGISTRY ABB=ON  PLU=ON  L23 NOT L9
```

=> d que stat l18
L14 STR



Page 1-A

11

Page 1-B
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE
L18 0 SEA FILE=BEILSTEIN SSS FUL L14

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.02

=> d que stat l20
L14 STR



Page 1-A

11

Page 1-B
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE
L20 0 SEA FILE=CHEMINFORMRX SSS FUL L14 (0 REACTIONS)

100.0% DONE 0 VERIFIED 0 HIT RXNS 0 DOCS
SEARCH TIME: 00.00.02

=> d que stat l22
L14 STR



Page 1-A

11

Page 1-B
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 35

STEREO ATTRIBUTES: NONE
L22 0 SEA FILE=MARPAT SSS FUL L14

100.0% PROCESSED 42 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

```
=> d his l20-l32

     (FILE 'CHEMINFORMRX' ENTERED AT 12:18:59 ON 30 MAY 2006)
L20            0 S L14 FUL
                 SAVE TEMP L20 GEM354CHM1/A

     FILE 'STNGUIDE' ENTERED AT 12:20:12 ON 30 MAY 2006

     FILE 'MARPAT' ENTERED AT 12:20:15 ON 30 MAY 2006
L21            0 S L14 SAM
L22            0 S L14 FUL
                 SAVE TEMP L22 GEM354MAR1/A

     FILE 'STNGUIDE' ENTERED AT 12:21:44 ON 30 MAY 2006

     FILE 'REGISTRY' ENTERED AT 12:23:18 ON 30 MAY 2006
L23            1 S 724770-27-8/RN,CRN
L24            0 S L23 NOT L9

     FILE 'STNGUIDE' ENTERED AT 12:23:45 ON 30 MAY 2006

     FILE 'WPIX' ENTERED AT 12:24:13 ON 30 MAY 2006
                 SELECT L2 1- DCRE
L25           98 S E13-E110/DCSE

     FILE 'STNGUIDE' ENTERED AT 12:25:32 ON 30 MAY 2006

     FILE 'WPIX' ENTERED AT 12:26:09 ON 30 MAY 2006
L26            1 S L25 AND (C27 H33 I N4 O3)/MF
                 SELECT L26 1- DCSE
L27            1 S E111/KW
L28            0 S L14 SAM
L29            1 S L14 FUL
L30            1 S L29/DCR
                 SELECT L29 1- SDCN
L31            1 S E112/DCN
L32            1 S L27 OR L30 OR L31

=> d que stat l32
L14              STR
```



Page 1-A

11

```
Page 1-B
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  35

STEREO ATTRIBUTES: NONE
L27             1 SEA FILE=WPIX ABB=ON  PLU=ON  933801-0-0-0/KW
L29             1 SEA FILE=WPIX SSS FUL L14
L30             1 SEA FILE=WPIX ABB=ON  PLU=ON  L29/DCR
L31             1 SEA FILE=WPIX ABB=ON  PLU=ON  RAEX6A/DCN
L32             1 SEA FILE=WPIX ABB=ON  PLU=ON  L27 OR L30 OR L31



=> d his l11

     (FILE 'HCAPLUS, TOXCENTER, USPATFULL' ENTERED AT 12:11:11 ON 30 MAY 2006)
L11             3 S L9

=> d que stat l11
L1              1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2003-743354/APPS
L3                TRANSFER  PLU=ON  L1 1- RN  :     387 TERMS
L4            387 SEA FILE=REGISTRY ABB=ON  PLU=ON  L3
L5            131 SEA FILE=REGISTRY ABB=ON  PLU=ON  L4 AND ?NAPHTHYRIDIN?/CNS
L9              1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5 AND I/ELS
L11             3 SEA L9


=> dup rem l11 l18 l20 l22 l32
L18 HAS NO ANSWERS
L20 HAS NO ANSWERS
L22 HAS NO ANSWERS
DUPLICATE IS NOT AVAILABLE IN 'BEILSTEIN, CHEMINFORMRX'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
FILE 'HCAPLUS' ENTERED AT 13:00:18 ON 30 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 13:00:18 ON 30 MAY 2006
COPYRIGHT (C) 2006 ACS

FILE 'USPATFULL' ENTERED AT 13:00:18 ON 30 MAY 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 13:00:18 ON 30 MAY 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION
PROCESSING COMPLETED FOR L11
PROCESSING COMPLETED FOR L18
PROCESSING COMPLETED FOR L20
PROCESSING COMPLETED FOR L22
PROCESSING COMPLETED FOR L32
L68             2 DUP REM L11 L18 L20 L22 L32 (2 DUPLICATES REMOVED)
                  ANSWER '1' FROM FILE HCAPLUS
```

ANSWER '2' FROM FILE USPATFULL

=> file stnguide
FILE 'STNGUIDE' ENTERED AT 13:00:24 ON 30 MAY 2006

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 26, 2006 (20060526/UP).

=> d ibib ed ab ind hitstr
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L68 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2004:565087 HCAPLUS
DOCUMENT NUMBER: 141:123408
TITLE: Heteroarylalkanoic acids as integrin receptor antagonists
INVENTOR(S): Boys, Mark L.; Schretzman, Lori A.; Tollefson, Michael B.; Chandrakumar, Nizal S.; Khanna, Ish K.; Nguyen, Maria; Downs, Victoria; Mohler, Scott B.; Gesicki, Glen J.; Penning, Thomas D.; Chen, Barbara B.; Wang, Yaping; Khilevich, Albert; Desai, Bipinchandra N.; Yu, Yi; Wendt, John A.; Stenmark, Heather; Wu, Lisa; Huff, Renee M.; Nagarajan, Srinivasan R.; Devadas, Balekudru; Lu, Hwang-fun; Russell, Mark; Spangler, Dale P.; Parikh, Mihir D.; Clare, Michael
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 266 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004058254	A1	20040715	WO 2003-US40898		20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2507699	AA	20040715	CA 2003-2507699		20031222
AU 2003299807	A1	20040722	AU 2003-299807		20031222
US 2005043344	A1	20050224	US 2003-743354		20031222
EP 1592421	A1	20051109	EP 2003-800081		20031222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003017600	A	20051129	BR 2003-17600		20031222
PRIORITY APPLN. INFO.:			US 2002-435467P	P	20021220
			WO 2003-US40898	W	20031222

OTHER SOURCE(S): MARPAT 141:123408
ED Entered STN: 15 Jul 2004
AB The present invention relates to pharmaceutical compns. comprising compds. I [A = (un)saturated and/or (un)substituted 4-8 membered monocyclic or 7-12 membered bicyclic ring, containing 1 to 5 heteroatoms selected from the group consisting of O, N or S; ring A may further contain a carboxamide, sulfone, sulfonamide, or an acyl group; A1 = (un)saturated and/or (un)substituted 5-9 membered monocyclic or 8-14 membered polycyclic heterocycle containing at least one N; or A1 = substituted urea, iminourea or thiourea alicyclic or cyclic analog; Z1 = CH2, CH2O, O, NH, CO, S, SO, CHOH, SO2; Z2 = (un)substituted 1-5 carbon linker optionally containing one or

more heteroatoms; alternatively Z1-Z2 may contain a carboxamide, sulfone, sulfonamide, alkenyl, acyl group, or aryl or heteroaryl ring; X = CO, SO2, S, O, substituted amine, substituted CH; Y = CO, SO2, substituted amine, etc.; Y5 = C or N; Y3 and Y4 independently = H, halo, (un)substituted-alkyl, -aryl, -alkene, etc.; or Y3 and Y4 together form a (un)saturated and/or (un)substituted 3-8 membered monocyclic or a 7-11 membered bicyclic ring optionally containing heteroatoms; or X and Y3 form a 3-7 membered monocyclic ring optionally containing heteroatoms; Rb = OH, alkoxy, arylamine, etc.], or a pharmaceutically acceptable salt thereof, methods of selectively inhibiting or antagonizing the αvβ3 and/or the αvβ5 integrin without significantly inhibiting the αvβ6 integrin, and methods to prepare I. Thus, e.g., II was prepared in four steps with oxadiazole ring forming via cyclization reaction of amide oxime III with cyclic anhydride IV (preparation given). I antagonize αvβ3 integrin with an IC50 values ranging from 0.1 nM to 100 μM in the 293-cell assay. Similarly, I also antagonized αvβ5 integrin with an IC50 values of < 50 μM in the cell adhesion assay.

IC ICM A61K031-4245
ICS A61P019-02; A61P019-10; A61P027-00; A61P035-00; A61P035-04; A61P043-00

CC 23-16 (Aliphatic Compounds)
Section cross-reference(s): 1, 28, 63

ST butanoic acid heteroaryl deriv prepn integrin receptor antagonist; alkanoic acid heteroaryl deriv prepn integrin receptor antagonist

IT Neoplasm
(humoral hypercalcemia of malignancy; preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT Eye, disease
(macula, degeneration; preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT Neoplasm
(metastasis; preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT Angiogenesis
Antiarteriosclerotics
Antiarthritics
Antitumor agents
Arthritis
Atherosclerosis
Drug delivery systems
Osteoporosis
(preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT Artery, disease
(restenosis; preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT Eye, disease
(retinopathy; preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT Cell migration
(smooth muscle; preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(αvβ3; preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT Integrins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(αvβ5; preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT 724769-51-1P
RL: BPN (Biosynthetic preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT 17004-92-1P
RL: BPN (Biosynthetic preparation); PUR (Purification or recovery); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT 724770-81-4P 724770-82-5P 724770-83-6P 724770-84-7P 724770-85-8P
724770-86-9P
RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT 724771-32-8P 724771-34-0P
RL: BYP (Byproduct); PREP (Preparation)
(preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT 381677-42-5P 724768-22-3P 724768-23-4P 724768-25-6P 724768-27-8P
724768-29-0P 724768-31-4P 724768-33-6P 724768-35-8P 724768-37-0P
724768-38-1P 724768-39-2P 724768-40-5P 724768-41-6P 724768-42-7P
724768-43-8P 724768-44-9P 724768-45-0P 724768-46-1P 724768-48-3P
724768-50-7P 724768-51-8P 724768-52-9P 724768-53-0P 724768-54-1P
724768-55-2P 724768-56-3P 724768-57-4P 724768-58-5P 724768-59-6P
724768-61-0P 724768-63-2P 724768-65-4P 724768-67-6P 724768-69-8P
724768-71-2P 724768-73-4P 724768-75-6P 724768-76-7P 724768-77-8P
724768-78-9P 724768-81-4P 724768-82-5P 724768-84-7P 724768-86-9P
724768-88-1P 724768-89-2P 724768-91-6P 724768-92-7P 724768-94-9P
724768-96-1P 724768-97-2P 724768-98-3P 724769-00-0P 724769-02-2P
724769-03-3P 724769-05-5P 724769-06-6P 724769-08-8P 724769-09-9P
724769-11-3P 724769-13-5P 724769-14-6P 724769-15-7P 724769-16-8P
724769-17-9P 724769-18-0P 724769-20-4P 724769-22-6P 724769-24-8P
724769-26-0P 724769-28-2P 724769-30-6P 724769-32-8P 724769-35-1P
724769-37-3P 724769-38-4P 724769-39-5P 724769-41-9P 724769-42-0P
724769-44-2P 724769-46-4P 724769-47-5P 724769-48-6P 724769-49-7P
724769-50-0P 724769-52-2P 724769-53-3P 724769-54-4P 724769-57-7P
724769-59-9P 724769-60-2P 724769-61-3P 724769-63-5P 724769-65-7P
724769-67-9P 724769-69-1P 724769-71-5P 724769-73-7P 724769-75-9P
724769-77-1P 724769-79-3P 724769-80-6P 724769-81-7P 724769-83-9P
724769-84-0P 724769-86-2P 724769-87-3P 724769-89-5P 724769-91-9P
724769-93-1P 724769-95-3P 724769-97-5P 724769-98-6P 724770-02-9P

724770-03-0P 724770-05-2P 724770-07-4P 724770-09-6P 724770-11-0P
724770-12-1P 724770-13-2P 724770-14-3P 724770-16-5P 724770-18-7P
724770-20-1P 724770-22-3P 724770-25-6P **724770-27-8P**
724770-29-0P 724770-31-4P 724770-33-6P 724770-35-8P 724770-37-0P
724770-39-2P 724771-75-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT 67-36-7, 4-Phenoxybenzaldehyde 67-64-1, Acetone, reactions 79-19-6, Thiosemicarbazide 105-53-3, Diethyl malonate 105-56-6, Ethyl cyanoacetate 105-58-8, Diethylcarbonate 109-70-6, 1-Bromo-3-chloropropane 110-89-4, Piperidine, reactions 110-91-8, Morpholine, reactions 120-14-9, 3,4-Dimethoxybenzaldehyde 120-57-0, Piperonal 123-90-0, Thiomorpholine 140-88-5, Ethyl acrylate 141-97-9, Ethyl acetoacetate 351-54-2, 3-Fluoro-4-methoxybenzaldehyde 403-54-3, 3-Fluorobenzonitrile 455-19-6, 4-Trifluoromethylbenzaldehyde 461-96-1, 1-Bromo-3,5-difluorobenzene 498-60-2, 3-Furaldehyde 498-62-4, 3-Thiophenecarboxaldehyde 613-92-3 617-90-3, 2-Furonitrile 626-67-5, N-Methylpiperidine 656-42-8, 2,2-Difluoro-1,3-benzodioxole-5-carboxaldehyde 659-28-9, 4-Trifluoromethoxybenzaldehyde 695-34-1, 2-Amino-4-picoline 704-13-2, 3-Hydroxy-4-nitrobenzaldehyde 825-60-5 867-13-0, Triethylphosphonoacetate 1003-60-7, 2-Methyl-5-thiazolecarboxaldehyde 1824-81-3, 2-Amino-6-picoline 2227-79-4, Benzenecarbothioamide 2362-64-3, 4-Methoxythiobenzamide 2521-24-6, 4-Chlorothiobenzamide 2525-16-8 3162-29-6 3453-33-6, 6-Methoxy-2-naphthaldehyde 4265-16-1, 2-Benzofurancarboxaldehyde 4397-53-9, 4-Benzyloxybenzaldehyde 4926-12-9 5164-76-1 5398-77-6, 4-Methylsulfonylbenzaldehyde 5464-11-9, 2-Methylthio-2-imidazoline hydriodide 5693-62-9 5717-37-3, (Carbethoxyethylidene)triphenylphosphorane 6287-38-3, 3,4-Dichlorobenzaldehyde 6610-29-3, 4-Methyl-3-thiosemicarbazide 6938-68-7, 2-Methyl-3-thiosemicarbazide 7311-34-4, 3,5-Dimethoxybenzaldehyde 10203-08-4, 3,5-Dichlorobenzaldehyde 13472-85-0, 5-Bromo-2-methoxypyridine 15128-90-2, 3-Hydroxy-6-methyl-2-nitropyridine 19798-80-2, 4-Chloropyridin-2-amine 19798-81-3, 2-Amino-6-bromopyridine 26690-80-2, tert-Butyl N-(2-hydroxyethyl)carbamate 29335-36-2 29668-44-8 30529-70-5, 2-Chloro-6-methylnicotinic acid 32085-88-4, 3,5-Difluorobenzaldehyde 36437-19-1 52605-49-9, Sarcosine ethyl ester hydrochloride 52771-21-8, 3-Trifluoromethoxybenzaldehyde 54605-72-0 55234-58-7 58885-58-8, tert-Butyl (3-hydroxypropyl)carbamate 63837-11-6, 5-Bromo-2-methylbenzothiazole 64248-62-0, 3,4-Difluorobenzonitrile 64248-63-1, 3,5-Difluorobenzonitrile 65873-72-5, 6-Methoxynicotinaldehyde 71144-35-9, 3-Fluoro-4,5-dihydroxybenzaldehyde 91963-19-8 132123-54-7, 3,4,5-Trifluorobenzaldehyde 135579-85-0, 3-Cyanopropylzinc bromide 177756-62-6, 3-Fluoro-4-methylbenzaldehyde 188815-30-7, 3-Fluoro-5-trifluoromethylbenzaldehyde 193818-28-9 204452-95-9 227938-79-6, 1,8-Naphthyridine-2-butanenitrile 227938-80-9 339555-37-2 381226-86-4 381677-47-0 381677-75-4 689259-14-1 722549-30-6 724770-52-9 724771-55-5 724771-56-6 724771-58-8 724771-60-2 724771-61-3 724771-62-4 724771-63-5 724771-64-6 724771-65-7 724771-66-8 724771-67-9 724771-68-0 724771-69-1 724771-70-4 724771-71-5 724771-72-6 724771-73-7 724771-74-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT 1569-16-0P, 2-Methyl-1,8-naphthyridine 4759-64-2P 6286-69-7P

17005-13-9P 20348-10-1P 20348-16-7P 20567-67-3P 29578-39-0P,
3-Bromo-5-fluoroanisole 40288-65-1P 52311-35-0P 55656-25-2P
64942-87-6P 68638-67-5P 72505-20-5P, 3-Fluorothiobenzamide
89026-79-9P 158471-13-7P 163083-48-5P 243641-39-6P 332884-21-6P
381226-84-2P 381226-85-3P 445490-28-8P 477207-32-2P 689259-06-1P
689259-07-2P 689259-08-3P 689259-09-4P 689259-10-7P 689259-11-8P
689259-12-9P 689259-13-0P 689259-29-8P 689259-30-1P 689259-31-2P
689259-32-3P 689259-33-4P 689259-34-5P 721920-79-2P 721920-80-5P
721920-81-6P 721920-84-9P 721920-85-0P 721920-90-7P 721920-95-2P
721920-96-3P 721920-97-4P 721920-98-5P 721920-99-6P 722549-91-9P
722549-92-0P 722549-93-1P 722549-94-2P 724770-46-1P 724770-48-3P
724770-49-4P 724770-50-7P 724770-51-8P 724770-53-0P 724770-54-1P
724770-55-2P 724770-56-3P 724770-57-4P 724770-58-5P 724770-59-6P
724770-60-9P 724770-61-0P 724770-62-1P 724770-63-2P 724770-64-3P
724770-65-4P 724770-66-5P 724770-67-6P 724770-68-7P 724770-69-8P
724770-71-2P 724770-73-4P 724770-74-5P 724770-76-7P 724770-78-9P
724770-79-0P 724770-80-3P 724770-87-0P 724770-88-1P 724770-89-2P
724770-90-5P 724770-91-6P 724770-92-7P 724770-94-9P 724770-95-0P
724770-96-1P 724770-97-2P 724770-98-3P 724771-00-0P 724771-01-1P
724771-02-2P 724771-04-4P 724771-05-5P 724771-06-6P 724771-07-7P
724771-08-8P 724771-09-9P 724771-10-2P 724771-11-3P 724771-12-4P
724771-13-5P 724771-14-6P 724771-15-7P 724771-16-8P 724771-18-0P
724771-19-1P 724771-21-5P 724771-23-7P 724771-24-8P 724771-25-9P
724771-26-0P 724771-28-2P 724771-30-6P 724771-33-9P 724771-35-1P
724771-36-2P 724771-37-3P 724771-39-5P 724771-40-8P 724771-41-9P
724771-42-0P 724771-43-1P 724771-44-2P 724771-45-3P 724771-46-4P
724771-47-5P 724771-48-6P 724771-49-7P 724771-50-0P 724771-51-1P
724771-52-2P 724771-53-3P 724771-54-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

IT **724770-27-8P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

RN 724770-27-8 HCAPLUS
CN 1,2,4-Oxadiazole-5-butanoic acid, β-[3-(1,1-dimethylethyl)-5-iodophenyl]-3-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)



=> d ibib ab hitstr 2
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, USPATFULL' - CONTINUE? (Y)/N:y

L68 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2005:50544 USPATFULL

TITLE: Heteroarylalkanoic acids as integrin receptor antagonists derivatives

INVENTOR(S): Boys, Mark L., Brighton, MI, UNITED STATES
Schretzman, Lori A., East Hanover, NJ, UNITED STATES
Tollefson, Michael B., Dardenne Prairie, MO, UNITED STATES
Chandrakumar, Nizal Samuel, Grafton, MA, UNITED STATES
Khanna, Ish Kumar, Libertyville, IL, UNITED STATES
Nguyen, Maria, Ann Arbor, MI, UNITED STATES
Downs, Victoria L., Pinckney, MI, UNITED STATES
Mohler, Scott B., Chicago, IL, UNITED STATES
Gesicki, Glen J., Chicago, IL, UNITED STATES
Penning, Thomas D., Elmhurst, IL, UNITED STATES
Chen, Barbara B., Glenview, IL, UNITED STATES
Wang, Yaping, Acton, MA, UNITED STATES
Khilevich, Albert, Buffalo Grove, IL, UNITED STATES
Desai, Bipinchandra N., Vernon Hills, IL, UNITED STATES
Yu, Yi, Glenview, IL, UNITED STATES
Wendt, John A., South Lyon, MI, UNITED STATES
Stenmark, Heather, Chicago, IL, UNITED STATES
Wu, Hongwei, Buffalo Grove, IL, UNITED STATES
Huff, Renee M., Park Ridge, IL, UNITED STATES
Nagarajan, Srinivasan Raj, Chesterfield, MO, UNITED STATES
Devadas, Balekudru, Chesterfield, MO, UNITED STATES
Lu, Hwang-Fun, Ballwin, MO, UNITED STATES
Russell, Mark, Gurnee, IL, UNITED STATES
Spangler, Dale P., San Diego, CA, UNITED STATES
Parikh, Mihir D., Chesterfield, MO, UNITED STATES

PATENT ASSIGNEE(S): Pharmacia Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005043344	A1	20050224
APPLICATION INFO.:	US 2003-743354	A1	20031222 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-435467P	20021220 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SENNIGER POWERS LEAVITT AND ROEDEL, ONE METROPOLITAN SQUARE, 16TH FLOOR, ST LOUIS, MO, 63102
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
LINE COUNT: 6480
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to pharmaceutical compositions comprising compounds of the Formula I, or a pharmaceutically acceptable salt thereof, and methods of selectively inhibiting or antagonizing the α.sub.Vβ.sub.3 and/or the α.sub.Vβ.sub.5 integrin without significantly inhibiting the α.sub.Vβ.sub.6 integrin.

IT **724770-27-8P**
(preparation of heteroaryl butanoic acid derivs. as selective inhibitors or antagonists of αvβ3 and/or αvβ5 integrin receptor)

RN 724770-27-8 USPATFULL
CN 1,2,4-Oxadiazole-5-butanoic acid, β-[3-(1,1-dimethylethyl)-5-iodophenyl]-3-[3-(1,5,6,7-tetrahydro-1,8-naphthyridin-2-yl)propyl]- (9CI) (CA INDEX NAME)



```
=> d his l67

     (FILE 'HCAPLUS, MEDLINE, BIOSIS, PASCAL, JICST-EPLUS, CABA, LIFESCI,
     DRUGU, DRUGB, VETU, VETB, WPIX, SCISEARCH, CONF, CONFSCI, DISSABS'
     ENTERED AT 12:37:36 ON 30 MAY 2006)
L67          11 DUP REM L66 (10 DUPLICATES REMOVED)

=> d que stat l67
L33             QUE  ABB=ON  PLU=ON  BOYS, M?/AU
L34             QUE  ABB=ON  PLU=ON  SCHRETZMAN, L?/AU
L35             QUE  ABB=ON  PLU=ON  TOLLEFSON, M?/AU
L36             QUE  ABB=ON  PLU=ON  CHANDRAKUMAR, N?/AU
L37             QUE  ABB=ON  PLU=ON  KHANNA, I?/AU
L38             QUE  ABB=ON  PLU=ON  NGUYEN, M?/AU
L39             QUE  ABB=ON  PLU=ON  DOWNS, V?/AU
L40             QUE  ABB=ON  PLU=ON  MOHLER, S?/AU
L41             QUE  ABB=ON  PLU=ON  GESICKI, G?/AU
L42             QUE  ABB=ON  PLU=ON  PENNING, T?/AU
L43             QUE  ABB=ON  PLU=ON  CHEN, B?/AU
L44             QUE  ABB=ON  PLU=ON  WANG, Y?/AU
L45             QUE  ABB=ON  PLU=ON  KHILEVICH, A?/AU
L46             QUE  ABB=ON  PLU=ON  DESAI, B?/AU
L47             QUE  ABB=ON  PLU=ON  YU, Y?/AU
L48             QUE  ABB=ON  PLU=ON  WENDT, J?/AU
L49             QUE  ABB=ON  PLU=ON  STENMARK, H?/AU
L50             QUE  ABB=ON  PLU=ON  WU, H?/AU
L51             QUE  ABB=ON  PLU=ON  HUFF, R?/AU
L52             QUE  ABB=ON  PLU=ON  NAGARAJAN, S?/AU
L53             QUE  ABB=ON  PLU=ON  DEVADAS, B?/AU
L54             QUE  ABB=ON  PLU=ON  LU, H?/AU
L55             QUE  ABB=ON  PLU=ON  RUSSEL, M?/AU
L56             QUE  ABB=ON  PLU=ON  SPANGLER, D?/AU
L57             QUE  ABB=ON  PLU=ON  PARIKH, M?/AU
L58             QUE  ABB=ON  PLU=ON  PHARMACIA/PA,CS,SO
L62       10520 SEA (L33 OR L34 OR L35 OR L36 OR L37) OR (L39 OR L40 OR L41 OR
                L42) OR (L45 OR L46) OR (L48 OR L49) OR (L51 OR L52 OR L53) OR
                (L55 OR L56 OR L57)
L63         215 SEA (L38 OR L43 OR L44 OR L47 OR L50 OR L54) AND L58
L64          94 SEA (L62 OR L63) AND ?INTEGRIN?
L65          85 SEA L64 AND (?INTEGRIN?(L)(?ANTAGON? OR ?INHIBIT? OR ?PROHIBIT?
                 OR ?BLOCK? OR STOP? OR DISRUPT? OR INTERRUPT? OR CONTROL? OR
                MODERAT? OR MODULAT? OR ?REGULAT? OR ?PREVENT? OR ?REDUC? OR
                ?IMPED? OR ?SUPPRESS? OR REPRESS? OR RETARD? OR SLOW?))
L66          21 SEA L65 AND (ALKANOIC? OR HETEROALKANOIC? OR ?BUTANOIC?)
L67          11 DUP REM L66 (10 DUPLICATES REMOVED)


=> d ibib ed ab l67 1-11
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS, BIOSIS' - CONTINUE? (Y)/N:y


L67  ANSWER 1 OF 11  HCAPLUS  COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2006:16564  HCAPLUS
DOCUMENT NUMBER:          144:254037
TITLE:                    Synthesis of 2,5-thiazole butanoic acids as
                          potent and selective αvβ3  integrin
                          receptor antagonists with improved oral
                          pharmacokinetic properties
AUTHOR(S):                Wendt, John A.; Wu, Hongwei; Stenmark,
```

Heather G.; Boys, Mark L.; Downs, Victoria L.; Penning, Thomas D.; Chen, Barbara B.; Wang, Yaping; Duffin, Tiffany; Finn, Mary Beth; Keene, Jeffery L.; Engleman, V. Wayne; Freeman, Sandra K.; Hanneke, Melanie L.; Shannon, Kristen E.; Nickols, Maureen A.; Steininger, Christina N.; Westlin, Marissa; Klover, Jon A.; Westlin, William; Nickols, G. Allen; Russell, Mark A.

CORPORATE SOURCE: Department of Medicinal Chemistry, Pfizer Global Research and Development, Ann Arbor, MI, 48105, USA

SOURCE: Bioorg. Med. Chem. Lett. (2006), 16(4), 845-849
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:254037

ED Entered STN: 08 Jan 2006

AB A series of 2,5-thiazoles, e.g. I [R = 3-FC6H4, 3,4-(MeO)2C6H3, 6-methoxy-3-pyridyl, 2-phenyl-5-thiazolyl, etc.], which are potent **antagonists** of the **integrin** αvβ3 and show selectivity relative to the other **integrins**, such as αIIbβ3 and αvβ6, has been synthesized. These analogs were demonstrated to have high bioavailability relative to other relative heterocyclic analogs.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 2 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2006:16560 HCAPLUS

DOCUMENT NUMBER: 144:254069

TITLE: Convergent, parallel synthesis of a series of β-substituted 1,2,4-oxadiazole **butanoic** acids as potent and selective αvβ3 receptor antagonists

AUTHOR(S): **Boys, Mark L.; Schretzman, Lori A.; Chandrakumar, Nizal S.; Tollefson, Michael B.; Mohler, Scott B.; Downs, Victoria L.; Penning, Thomas D.**; Russell, Mark A.; **Wendt, John A.**; Chen, Barbara B.; **Stenmark, Heather G.**; Wu, Hongwei; **Spangler, Dale P.**; Clare, Michael; **Desai, Bipin N.; Khanna, Ish K.**; Nguyen, Maria N.; Duffin, Tiffany; Engleman, V. Wayne; Finn, Mary Beth; Freeman, Sandra K.; Hanneke, Melanie L.; Keene, Jeffery L.; Klover, Jon A.; Nickols, G. Allen; Nickols, Maureen A.; Steininger, Christina N.; Westlin, Marisa; Westlin, William; Yu, Yi X.; Wang, Yaping; Dalton, Christopher R.; Norring, Sarah A.

CORPORATE SOURCE: Department of Chemistry, PfizerGlobal Research and Development, Ann Arbor, MI, 48105, USA

SOURCE: Bioorg. Med. Chem. Lett. (2006), 16(4), 839-844
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:254069

ED Entered STN: 08 Jan 2006

AB A series of 1,2,4-oxadiazoles, e.g. I [R1 = H, R2 = H, Me, HC.tplbond.C, Ph, 3-pyridyl, 2-methyl-5-thiazolyl, etc.; R1 = Me, R2 = Me, Ph, 3-pyridyl; R1R2 = (CH2)4], which are potent **antagonists** of the

integrin αvβ3 and, in addition, show selectivity relative to the other β3 **integrin** αIIbβ3, has been synthesized. In whole cells, the majority of these analogs also demonstrated modest selectivity against other αv **integrins** such as αvβ1 and αvβ6.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 3 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2004:565087 HCAPLUS
DOCUMENT NUMBER: 141:123408
TITLE: Heteroarylalkanoic acids as **integrin** receptor **antagonists**
INVENTOR(S): **Boys, Mark L.**; **Schretzman, Lori A.**; **Tollefson, Michael B.**; **Chandrakumar, Nizal S.**; **Khanna, Ish K.**; **Nguyen, Maria**; **Downs, Victoria**; **Mohler, Scott B.**; **Gesicki, Glen J.**; **Penning, Thomas D.**; **Chen, Barbara B.**; **Wang, Yaping**; **Khilevich, Albert**; **Desai, Bipinchandra N.**; **Yu, Yi**; **Wendt, John A.**; **Stenmark, Heather**; Wu, Lisa; **Huff, Renee M.**; **Nagarajan, Srinivasan R.**; **Devadas, Balekudru**; **Lu, Hwang-fun**; Russell, Mark; **Spangler, Dale P.**; **Parikh, Mihir D.**; Clare, Michael
PATENT ASSIGNEE(S): **Pharmacia** Corporation, USA
SOURCE: PCT Int. Appl., 266 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058254	A1	20040715	WO 2003-US40898	20031222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507699	AA	20040715	CA 2003-2507699	20031222
AU 2003299807	A1	20040722	AU 2003-299807	20031222
US 2005043344	A1	20050224	US 2003-743354	20031222
EP 1592421	A1	20051109	EP 2003-800081	20031222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017600	A	20051129	BR 2003-17600	20031222
PRIORITY APPLN. INFO.:			US 2002-435467P P	20021220
			WO 2003-US40898 W	20031222

OTHER SOURCE(S): MARPAT 141:123408
ED Entered STN: 15 Jul 2004
AB The present invention relates to pharmaceutical compns. comprising compds.

I [A = (un)saturated and/or (un)substituted 4-8 membered monocyclic or 7-12 membered bicyclic ring, containing 1 to 5 heteroatoms selected from the group consisting of O, N or S; ring A may further contain a carboxamide, sulfone, sulfonamide, or an acyl group; A1 = (un)saturated and/or (un)substituted 5-9 membered monocyclic or 8-14 membered polycyclic heterocycle containing at least one N; or A1 = substituted urea, iminourea or thiourea alicyclic or cyclic analog; Z1 = CH2, CH2O, O, NH, CO, S, SO, CHOH, SO2; Z2 = (un)substituted 1-5 carbon linker optionally containing one or more heteroatoms; alternatively Z1-Z2 may contain a carboxamide, sulfone, sulfonamide, alkenyl, acyl group, or aryl or heteroaryl ring; X = CO, SO2, S, O, substituted amine, substituted CH; Y = CO, SO2, substituted amine, etc.; Y5 = C or N; Y3 and Y4 independently = H, halo, (un)substituted-alkyl, -aryl, -alkene, etc.; or Y3 and Y4 together form a (un)saturated and/or (un)substituted 3-8 membered monocyclic or a 7-11 membered bicyclic ring optionally containing heteroatoms; or X and Y3 form a 3-7 membered monocyclic ring optionally containing heteroatoms; Rb = OH, alkoxy, arylamine, etc.], or a pharmaceutically acceptable salt thereof, methods of selectively **inhibiting** or **antagonizing** the αvβ3 and/or the αvβ5 **integrin** without significantly **inhibiting** the αvβ6 **integrin**, and methods to prepare I. Thus, e.g., II was prepared in four steps with oxadiazole ring forming via cyclization reaction of amide oxime III with cyclic anhydride IV (preparation given). I **antagonize** αvβ3 **integrin** with an IC50 values ranging from 0.1 nM to 100 μM in the 293-cell assay. Similarly, I also **antagonized** αvβ5 **integrin** with an IC50 values of < 50 μM in the cell adhesion assay.

L67 ANSWER 4 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 5
ACCESSION NUMBER: 2001:923768 HCAPLUS
DOCUMENT NUMBER: 136:53681
TITLE: Preparation of cycloalkylalkanoic acids as **integrin** receptor **antagonists**
INVENTOR(S): **Khanna, Ish Kumar**; Clare, Michael; Gasiecki, Alan F.; Rogers, Thomas; **Chen, Barbara**; Russell, Mark; **Lu, Hwang-Fun**
PATENT ASSIGNEE(S): **Pharmacia** Corporation, USA
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096307	A2	20011220	WO 2001-US19104	20010615
WO 2001096307	A3	20020815		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1289960	A2	20030312	EP 2001-948363	20010615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

JP 2004525069	T2	20040819	JP 2002-510450		20010615
US 2004043988	A1	20040304	US 2003-311299		20030821
PRIORITY APPLN. INFO.:			US 2000-211781P	P	20000615
			WO 2001-US19104	W	20010615

OTHER SOURCE(S): MARPAT 136:53681
ED Entered STN: 21 Dec 2001
AB The preparation of compds. [I; A = heteroaryl (e.g., pyridine, imidazole, thiazole, oxazole, benzimidazole, imidazopyridine, etc.); n = 0-2, etc.; R1 = H, alkyl, etc.; R2, R3, R4, R5 = alkyl, alkoxy, etc.], their pharmaceutically acceptable salts and compns., and methods of selectively **inhibiting** or **antagonizing** the αvβ3 and/or αvβ5 **integrin**, are described. Thus, a multi-step synthesis of the trifluoroacetate salt of 2-[4-[3-(2-pyridinylamino)propoxy]phenyl]cyclopropaneacetic acid (II) is given. Administration of I **inhibits** angiogenesis, tumor metastasis, tumor growth, osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, retinopathy, macular degeneration, arthritis, periodontal disease, smooth muscle cell migration, including restenosis and atherosclerosis, and viral diseases.

L67 ANSWER 5 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:566608 HCAPLUS
DOCUMENT NUMBER: 141:123621
TITLE: Preparation of pyrazole derivatives as **integrin** receptor **antagonists**
INVENTOR(S): **Penning, Thomas D.**; **Khilevich, Albert**; **Chen, Barbara B.**; Gandhi, Preete; **Wang, Yaping**; **Downs, Victoria**; **Boys, Mark L.**; Russell, Mark; **Spangler, Dale P.**; **Huff, Renee M.**
PATENT ASSIGNEE(S): **Pharmacia** Corporation, USA
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058761	A1	20040715	WO 2003-US40630	20031219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507958	AA	20040715	CA 2003-2507958	20031219
AU 2003297409	A1	20040722	AU 2003-297409	20031219
US 2005004200	A1	20050106	US 2003-741860	20031219
EP 1572691	A1	20050914	EP 2003-814227	20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016875	A	20051025	BR 2003-16875	20031219
JP 2006513218	T2	20060420	JP 2004-563834	20031219
PRIORITY APPLN. INFO.:			US 2002-435168P	P 20021220

WO 2003-US40630 W 20031219

OTHER SOURCE(S): MARPAT 141:123621
ED Entered STN: 15 Jul 2004
AB Title compds. I [wherein M1 = heteroaryl, acyl, (un)substituted hydrocarbyl; R1 = O, CO, SOm, NHSO2, SO2NH, (un)substituted methylene or amino; m = 0-2; R4 = C or N; R5 = H, halo, (un)substituted hydrocarbyl, heteroaryl; R6 = an electron pair when R4 is nitrogen, or H, halo, (un)substituted hydrocarbyl, heterocyclo; or R4R5R6 = mono or bicyclic ring; X1 = O, CH2, CH2O, NH, CO, SOm, CH(OH), alkenyl, alkynyl; X2 = (un)substituted linker; X3 = heterocyclic; Z1 = H, HO, cyano, (un)substituted hydrocarbyl, heteroaryl; and pharmaceutically acceptable salts thereof] were prepared as **integrin** receptor **antagonists**. For example, 3-(1,3-benzodioxol-5-yl)-4-[1-methyl-5-[2-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethoxy]-1H-pyrazol-3-yl] **butanoic** acid (II) was given in a multiple-step synthesis starting from 2-aminonicotinaldehyde. The prepared title compds. I were tested for **inhibition** of αvβ3 and/or αvβ5 **integrin** receptors. Thus, I and their pharmaceutical compns. are useful for the treatment or **prevention** of conditions mediated by the αvβ3 or αvβ5 **integrin** receptor, such as tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis (no data).
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 6 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:566607 HCAPLUS
DOCUMENT NUMBER: 141:123614
TITLE: Preparation of thiazoles, in particular thiazole **butanoic** acid derivatives, as **integrin** receptor **antagonists**
INVENTOR(S): **Wendt, John A.**; **Stenmark, Heather**; Wu, Lisa; **Wang, Yaping**; **Chen, Barbara B.**; **Penning, Thomas D.**; **Downs, Victoria**; **Boys, Mark L.**; Russell, Mark; **Spangler, Dale P.**
PATENT ASSIGNEE(S): **Pharmacia** Corporation, USA
SOURCE: PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058760	A1	20040715	WO 2003-US40629	20031219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2510084	AA	20040715	CA 2003-2510084	20031219

AU 2003297408	A1	20040722	AU 2003-297408	20031219
US 2005004189	A1	20050106	US 2003-741056	20031219
EP 1572690	A1	20050914	EP 2003-814226	20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003016876	A	20051025	BR 2003-16876	20031219
PRIORITY APPLN. INFO.:			US 2002-435030P	P 20021220
			WO 2003-US40629	W 20031219

OTHER SOURCE(S): MARPAT 141:123614
ED Entered STN: 15 Jul 2004
AB Title compds. I [wherein R1 = CHR2, NR3, O, S, SO2, NHSO2, SO2NH, C(:O); R2 = H, OH, (un)substituted hydrocarbyl or alkoxy; R3 = H, (un)substituted hydrocarbyl, heteroaryl, or acyl; R4 = C, N; R5 = H, halo, (un)substituted hydrocarbyl, heteroaryl; R6 = electron pair when R4 = H; or R6 = H, halo, or (un)substituted hydrocarbyl; R7 = OH and derivs., SH and derivs., NH2 and derivs., etc.; Z1 = H, OH, CN, (un)substituted hydrocarbyl, heteroaryl; and pharmaceutically acceptable salts thereof] were prepared for selectively **inhibiting** or **antagonizing** the αvβ3 and/or αvβ5 **integrins** (vitronectin receptors). For example, condensation of 4-(1-methyl-1,2,3,4-tetrahydropyrido[2,3-b]pyrazin-6-yl)butanethioamide (11-step synthesis given) with Et 3-(1,3-benzodioxol-5-yl)-6-chloro-5-oxohexanoate in dioxane at reflux, followed by saponification of the in-situ formed ester using NaOH in EtOH, gave II. Selected αvβ3 and/or αvβ5 **integrin antagonists** I displayed AUC/oral dose ratios in the range of 1.8 - 6.8 when administered to rats. Thus, I and their pharmaceutical compns. are useful for the treatment of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis (no data).

L67 ANSWER 7 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:859471 HCAPLUS
DOCUMENT NUMBER: 143:115774
TITLE: Synthesis and tissue distribution of 14C-nonpeptide αvβ3 antagonists
AUTHOR(S): McKinnis, Bradley R.; Albin, Lesley A.; Doom, James P.; Gasiecki, Alan F.; Hotz, Kathy J.; Keene, Jeffery L.; **Khanna, Ish K.**; Kraus, Lori J.; Liley, Matt R.; Likos, John J.; **Nagarajan, Srinivasan**; Rogers, Thomas E.; Singh, Rajendra K.
CORPORATE SOURCE: Pfizer Global Research and Development, St. Louis, MO, USA
SOURCE: Synthesis and Applications of Isotopically Labelled Compounds, Proceedings of the International Symposium, 8th, Boston, MA, United States, June 1-5, 2003 (2004), Meeting Date 2003, 413-416. Editor(s): Dean, Dennis C.; Filer, Crist N.; McCarthy, Keith E. John Wiley & Sons Ltd.: Chichester, UK.
CODEN: 69FZAZ; ISBN: 0-470-86365-X
DOCUMENT TYPE: Conference
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:115774
ED Entered STN: 18 Oct 2004
AB Three peptidomimetic **integrin** αvβ3 **antagonists**, I (R = Me, 3-pyridyl; X = 14CH2) and II (X = 14CH2), are prepared; their **antagonism** of **integrin** αvβ3 and their distributions in the tissues of rats are determined 14C-labeled 2-(3-hydroxypropylamino)pyridine-1-oxide is prepared from 2-chloropyridine N-oxide hydrochloride and 3-amino-3-[14C]-aminopropanol;

Mitsunobu coupling with p-hydroxyphenyl-substituted esters, **redn** . of the N-oxide, and ester hydrolysis yields I (R = Me, 3-pyridyl; X = 14CH2) and II (X = 14CH2). I (R = Me; X = 14CH2) is generated in an attempted preparation of II (X = 14CH2); **reduction** of the N-oxide ester intermediate in the preparation of II (X = 14CH2) with palladium on carbon and cyclohexene in refluxing isopropanol leads to **reduction** of the N-oxide and cleavage of the cyclopropane ring rather than **reduction** of the N-oxide alone. **Reduction** of the N-oxide ester intermediate in the preparation of II (X = 14CH2) with triphenylphosphine and iron in refluxing acetic acid **reduces** the N-oxide without cleaving the cyclopropane. I (R = Me, 3-pyridyl; X = 14CH2) and II (X = 14CH2) are obtained with radiochem. purities of ≥ 97.4%. Tissue distribution, mass balance, and clearance studies for I (R = Me, 3-pyridyl; X = 14CH2) and II (X = 14CH2) are performed.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 8 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:923795 HCAPLUS
DOCUMENT NUMBER: 136:53749
TITLE: Preparation of heteroarylalkanoic acids as **integrin** receptor **antagonists**
INVENTOR(S): **Nagarajan, Scrinivasan Raj**; **Khanna, Ish Kumar**; **Tollefson, Michael B.**; **Mohler, Scott B.**; **Chen, Barbara**; Russell, Mark; **Devadas, Balekudru**; **Penning, Thomas D.**; **Schretzman, Lori A.**; **Spangler, Dale P.**; **Boys, Mark Laurence**; **Chandrakumar, Nizal Samuel**; **Lu, Hwang-Fun**
PATENT ASSIGNEE(S): **Pharmacia** Corporation, USA
SOURCE: PCT Int. Appl., 368 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2001096334	A2	20011220	WO 2001-US19375		20010615
WO 2001096334	A3	20020912			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 2002133023	A1	20020919	US 2001-881913		20010615
US 6933304	B2	20050823			
EP 1289983	A2	20030312	EP 2001-948424		20010615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2004511434	T2	20040415	JP 2002-510476		20010615
US 2004092497	A1	20040513	US 2003-311385		20030905
PRIORITY APPLN. INFO.:			US 2000-211781P	P	20000615
			US 2000-211782P	P	20000615

WO 2001-US19375 W 20010615

OTHER SOURCE(S): MARPAT 136:53749
ED Entered STN: 21 Dec 2001
AB Title compds. A1Z2Z1AXYY5(Y3)(Y4)CH2CORb [I; wherein ring A = (un)substituted 4-8 membered monocyclic or 7-12 membered bicyclic ring containing 1-4 heteroatoms, selected from O, N, or S; A1 = (un)substituted 5-9 membered monocyclic or 7-14 membered polycyclic heterocycle containing at least 1 N and optionally 1-4 heteroatoms or groups selected from O, N, S, SO2, or CO; Z1 = CH2, O, CH2O, NH, CO, S, SO, CH(OH), and SO2; Z2 = (un)substituted 1-5 C linker optionally containing 1 or more heteroatoms selected from O, S, and N; Z1Z2 may contain a carboxamide, sulfone, sulfonamide, alkenyl, alkynyl, acyl, or (un)substituted 5- or 6-membered (hetero)aryl; X = CHRe, NRf, O, S, SO2, or CO; Re = H, (cyclo)alkyl, alkoxy(alkyl), OH, alkynyl, alkenyl, haloalkyl, thioalkyl, or aryl; Rf = H, (halo)alkyl, aryl, or benzyl; Y = (CH2)p, CHRg, NRg, CO, or SO2; Rg = H, (halo)alkyl, alkoxyalkyl, alkynyl, (hetero)aryl, OH, alkoxy, or carboxyalkyl; p = 0-1; XY may contain acyl, alkyl, sulfonyl, amino, (thio)ether, carboxamido, sulfonamido, aminosulfonyl, or olefin; Y3 and Y4 = independently H, (halo)alkyl, halo, (hetero)aryl, hydroxyalkyl, alkynyl, etc.; Rb = X2Rh; X2 = O, S, or NRj; Rh and Rj = independently H, (ar)alkyl, acyl, or alkoxyalkyl; with provisos] and their pharmaceutically acceptable salts were prepared for selectively **antagonizing** the αvβ3 and/or the αvβ5 **integrin** without significantly **antagonizing** the fibrinogen IIb/IIIa **integrin**. For example, 3-(hydroxymethyl)benzonitrile was protected with 3,4-dihydro-2H-pyran (89%) and treated with HONH2•HCl to give the benzenecarboximidamide (98%). Cyclization with 3-methylglutaric anhydride in the presence of MeI (64%) and deprotection (98%) gave the Me 1,2,4-oxadiazolebutanoate (64%). Oxidation to the aldehyde, followed by **reductive** addition of 2-aminopyridine and workup, afforded the **oxadiazolebutanoic** acid (II). In vitronectin adhesion assays, I **antagonized** the αvβ3 **integrin** and the αvβ5 **integrin** with IC50 values of 0.1 nM to 100 μM and < 50 μM, resp. I are useful for the treatment of tumor metastasis, solid tumor growth, angiogenesis, osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration, restenosis, atherosclerosis, macular degeneration, retinopathy, and arthritis (no data).

L67 ANSWER 9 OF 11 HCAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2001:923771 HCAPLUS
DOCUMENT NUMBER: 136:53683
TITLE: Preparation of dihydrostilbene **alkanoic** acid derivatives useful as vitronectin antagonists
INVENTOR(S): Rogers, Thomas; Clare, Michael; Fun Lu, Hwang; Russell, Mark; Malecha, James W.; **Khanna, Ish Kumar**; **Penning, Thomas**; **Nagarajan, Srinivasan Raj**
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 163 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001096310	A1	20011220	WO 2001-US19330	20010615

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2001052500	A1	20011220	US 2001-882647	20010615
AU 2001068490	A5	20011224	AU 2001-68490	20010615
US 2002099209	A1	20020725	US 2001-882137	20010615
US 6720315	B2	20040413		
EP 1289959	A1	20030312	EP 2001-946439	20010615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004503540	T2	20040205	JP 2002-510453	20010615
US 6833366	B1	20041221	US 2003-657932	20030909
PRIORITY APPLN. INFO.:			US 2000-211780P P	20000615
			US 2001-882137 A3	20010615
			WO 2001-US19330 W	20010615

OTHER SOURCE(S): MARPAT 136:53683
ED Entered STN: 21 Dec 2001
AB The preparation of [I; wherein the "A ring" = 4-8 membered monocyclic, or 7-12 membered bicyclic heteroarene; A1 = 5-9 membered monocyclic, or 7-12 membered polycyclic heterocycle; Z1 = CH2, CH2O, O, NH, CO, S, etc.; Z2 = 1-5 carbon linker optionally substituted with O, S, or N; X = alkyl, O, amino, CO, etc.; Y = substituted C; Ra = H, alkyl, alkenyl, etc.; R1 = H, alkyl, hydroxy, etc.; R2 = H, alkyl, etc.; R3 = H, alkyl, halogen, etc.], or a pharmaceutically acceptable salt or composition thereof, and methods of selectively αvβ3 **inhibiting** or **antagonizing** the αvβ3 and/or the αvβ5 **integrin**, are described. Thus, a multi-step preparation of 3-[[3-(2-pyridinylamino)propoxy]phenyl]propanoic acid II was given. Administration of I **inhibits** angiogenesis, tumor metastasis, tumor growth, osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, retinopathy, macular degeneration, arthritis, periodontal disease, smooth muscle cell migration, including restenosis and atherosclerosis, and viral diseases.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 10 OF 11 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 4
ACCESSION NUMBER: 2006:29662 BIOSIS
DOCUMENT NUMBER: PREV200600040384
TITLE: Dihydrostilbene **alkanoic** acid derivatives.
AUTHOR(S): Rogers, Thomas [Inventor]; Clare, Michael [Inventor]; **Lu, Hwang-Fun** [Inventor]; Russell, Mark [Inventor]; Malecha, James W. [Inventor]; **Khanna, Ish Kumar** [Inventor]; **Penning, Thomas** [Inventor]; **Nagarajan, Srinivasan Raj** [Inventor]
CORPORATE SOURCE: Ballwin, MO USA
ASSIGNEE: **Pharmacia** Corporation
PATENT INFORMATION: US 06833366 20041221
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (DEC 21 2004)
CODEN: OGUPE7. ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 28 Dec 2005

Last Updated on STN: 28 Dec 2005
ED Entered STN: 28 Dec 2005
Last Updated on STN: 28 Dec 2005
AB The present invention relates to a class of compounds represented by the Formula 1. or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula 1, and methods of selectively **inhibiting** or **antagonizing** the alpha(v)beta(3)and/or the alpha(v)beta(5)**integrin.**

L67 ANSWER 11 OF 11 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2004:257549 BIOSIS
DOCUMENT NUMBER: PREV200400257507
TITLE: Dihydrostilbene **alkanoic** acid derivatives.
AUTHOR(S): Rogers, Thomas [Inventor, Reprint Author]; Clare, Michael [Inventor]; **Lu, Hwang-Fun** [Inventor]; Russell, Mark [Inventor]; Malecha, James W. [Inventor]; **Khanna, Ish Kumar** [Inventor]; **Penning, Thomas** [Inventor]; **Nagarajan, Srinivasan Raj** [Inventor]; **Stenmark, Heather** [Inventor]
CORPORATE SOURCE: Manchester, MO, USA
ASSIGNEE: **Pharmacia** Corporation
PATENT INFORMATION: US 6720315 20040413
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Apr 13 2004) Vol. 1281, No. 2. http://www.uspto.gov/web/menu/patdata.html. e-file. ISSN: 0098-1133 (ISSN print).
DOCUMENT TYPE: Patent
LANGUAGE: English
ENTRY DATE: Entered STN: 12 May 2004
Last Updated on STN: 12 May 2004
ED Entered STN: 12 May 2004
Last Updated on STN: 12 May 2004
AB The present invention relates to a class of compounds represented by the Formula 1. ##STR1## or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula 1, and methods of selectively **inhibiting** or **antagonizing** the alphaVbeta3 and/or the alphaVbeta5 **integrin.**

=> file stnguide
FILE 'STNGUIDE' ENTERED AT 13:02:32 ON 30 MAY 2006
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 26, 2006 (20060526/UP).

```
=> d his ful

     (FILE 'HOME' ENTERED AT 11:52:34 ON 30 MAY 2006)

     FILE 'STNGUIDE' ENTERED AT 11:52:41 ON 30 MAY 2006

     FILE 'ZCAPLUS' ENTERED AT 11:57:50 ON 30 MAY 2006
               E US2003-743354/APPS

     FILE 'HCAPLUS' ENTERED AT 11:58:09 ON 30 MAY 2006
L1             1 SEA ABB=ON  PLU=ON  US2003-743354/APPS
               SAVE TEMP L1 GEM354HCAAPP/A

     FILE 'STNGUIDE' ENTERED AT 11:58:26 ON 30 MAY 2006

     FILE 'HCAPLUS' ENTERED AT 11:58:33 ON 30 MAY 2006
               D SCAN

     FILE 'STNGUIDE' ENTERED AT 11:58:39 ON 30 MAY 2006

     FILE 'WPIX' ENTERED AT 11:58:57 ON 30 MAY 2006
L2             1 SEA ABB=ON  PLU=ON  US2003-743354/APPS
               SAVE TEMP L2 GEM354WPIAPP/A

     FILE 'STNGUIDE' ENTERED AT 11:59:20 ON 30 MAY 2006

     FILE 'REGISTRY' ENTERED AT 12:00:49 ON 30 MAY 2006

     FILE 'HCAPLUS' ENTERED AT 12:00:52 ON 30 MAY 2006
L3             TRA PLU=ON  L1 1- RN  :      387 TERMS

     FILE 'REGISTRY' ENTERED AT 12:00:55 ON 30 MAY 2006
L4           387 SEA ABB=ON  PLU=ON  L3
               SAVE TEMP L4 GEM354REGAPP/A

     FILE 'STNGUIDE' ENTERED AT 12:01:16 ON 30 MAY 2006

     FILE 'REGISTRY' ENTERED AT 12:01:30 ON 30 MAY 2006
L5           131 SEA ABB=ON  PLU=ON  L4 AND ?NAPHTHYRIDIN?/CNS
L6            80 SEA ABB=ON  PLU=ON  L5 AND ?OXADIAZOL?/CNS
L7             1 SEA ABB=ON  PLU=ON  L6 AND ?IODO?/CNS
               D SCAN

     FILE 'STNGUIDE' ENTERED AT 12:02:14 ON 30 MAY 2006

     FILE 'REGISTRY' ENTERED AT 12:06:06 ON 30 MAY 2006
L8             1 SEA ABB=ON  PLU=ON  L6 AND I/ELS
L9             1 SEA ABB=ON  PLU=ON  L5 AND I/ELS
L10            6 SEA ABB=ON  PLU=ON  L4 AND I/ELS
               D SCAN
               SAVE TEMP L9 GEM354ES/A
               D SCAN L9

     FILE 'STNGUIDE' ENTERED AT 12:08:14 ON 30 MAY 2006
               D QUE STAT L9

     FILE 'REGISTRY' ENTERED AT 12:09:19 ON 30 MAY 2006
               D IDE L9

     FILE 'STNGUIDE' ENTERED AT 12:09:20 ON 30 MAY 2006
```

```
     FILE 'HCAPLUS, TOXCENTER, USPATFULL' ENTERED AT 12:11:11 ON 30 MAY 2006
L11           3 SEA ABB=ON  PLU=ON  L9
                D SCAN
                SAVE TEMP L11 GEM354MULS1/A

     FILE 'STNGUIDE' ENTERED AT 12:11:53 ON 30 MAY 2006
                D SAVED

     FILE 'LREGISTRY' ENTERED AT 12:12:27 ON 30 MAY 2006
L12             STR 724770-27-8

     FILE 'BEILSTEIN' ENTERED AT 12:13:09 ON 30 MAY 2006
L13           0 SEA SSS FUL L12
                SAVE TEMP L13 GEM354BEI1/A
                D QUE STAT

     FILE 'LREGISTRY' ENTERED AT 12:14:18 ON 30 MAY 2006
L14             STR L12

     FILE 'REGISTRY' ENTERED AT 12:14:43 ON 30 MAY 2006
L15           0 SEA SSS SAM L14
                D QUE STAT

     FILE 'STNGUIDE' ENTERED AT 12:15:13 ON 30 MAY 2006

     FILE 'REGISTRY' ENTERED AT 12:15:55 ON 30 MAY 2006
L16           1 SEA SSS FUL L14
                SAVE TEMP L16 GEM354PSTR1/A
L17           0 SEA ABB=ON  PLU=ON  L16 NOT L9

     FILE 'BEILSTEIN' ENTERED AT 12:17:20 ON 30 MAY 2006
L18           0 SEA SSS FUL L14
                SAVE TEMP L18 GEM354BEI2/A

     FILE 'STNGUIDE' ENTERED AT 12:18:03 ON 30 MAY 2006

     FILE 'CHEMINFORMRX' ENTERED AT 12:18:59 ON 30 MAY 2006
L19           0 SEA SSS SAM L14 (     0 REACTIONS)
                D QUE STAT
L20           0 SEA SSS FUL L14 (     0 REACTIONS)
                SAVE TEMP L20 GEM354CHM1/A

     FILE 'STNGUIDE' ENTERED AT 12:20:12 ON 30 MAY 2006

     FILE 'MARPAT' ENTERED AT 12:20:15 ON 30 MAY 2006
L21           0 SEA SSS SAM L14
                D QUE STAT
L22           0 SEA SSS FUL L14
                SAVE TEMP L22 GEM354MAR1/A

     FILE 'STNGUIDE' ENTERED AT 12:21:44 ON 30 MAY 2006
                D SAVED

     FILE 'REGISTRY' ENTERED AT 12:23:18 ON 30 MAY 2006
L23           1 SEA ABB=ON  PLU=ON  724770-27-8/RN,CRN
L24           0 SEA ABB=ON  PLU=ON  L23 NOT L9

     FILE 'STNGUIDE' ENTERED AT 12:23:45 ON 30 MAY 2006
```

```
     FILE 'WPIX' ENTERED AT 12:24:13 ON 30 MAY 2006
                SELECT L2 1- DCRE
L25           98 SEA ABB=ON  PLU=ON  (518960-0-0-0/DCSE OR 933801-0-0-0/DCSE OR
                933802-0-0-0/DCSE OR 933811-0-0-0/DCSE OR 933817-0-0-0/DCSE OR
                933818-0-0-0/DCSE OR 933824-0-0-0/DCSE OR 933834-0-0-0/DCSE OR
                933841-0-1-0/DCSE OR 933858-0-1-0/DCSE OR 933859-0-1-0/DCSE OR
                933862-0-1-0/DCSE OR 933865-0-1-0/DCSE OR 933866-0-1-0/DCSE OR
                933867-0-1-0/DCSE OR 933869-0-1-0/DCSE OR 933870-0-0-0/DCSE OR
                933874-0-1-0/DCSE OR 933875-0-1-0/DCSE OR 933876-0-1-0/DCSE OR
                933878-0-1-0/DCSE OR 933881-0-1-0/DCSE OR 933882-0-1-0/DCSE OR
                933883-0-1-0/DCSE OR 933884-0-1-0/DCSE OR 933898-0-1-0/DCSE OR
                933899-0-1-0/DCSE OR 933903-0-1-0/DCSE OR 933907-0-1-0/DCSE OR
                933915-0-0-0/DCSE OR 933919-0-0-0/DCSE OR 933920-0-0-0/DCSE OR
                933923-0-0-0/DCSE OR 933926-0-1-0/DCSE OR 933929-0-1-0/DCSE OR
                933933-0-1-0/DCSE OR 933934-0-0-0/DCSE OR 933936-0-1-0/DCSE OR
                933937-0-0-0/DCSE OR 933939-0-1-0/DCSE OR 933941-0-0-0/DCSE OR
                933946-0-0-0/DCSE OR 933952-0-1-0/DCSE OR 933961-0-1-0/DCSE OR
                933965-0-1-0/DCSE OR 933977-0-1-0/DCSE OR 933979-0-1-0/DCSE OR
                934001-0-0-0/DCSE OR 934006-0-0-0/DCSE OR 934007-0-0-0/DCSE OR
                934008-0-0-0/DCSE OR 934009-0-0-0/DCSE OR 934010-0-0-0/DCSE OR
                934013-0-0-0/DCSE OR 934014-0-0-0/DCSE OR 934022-0-1-0/DCSE OR
                934025-0-0-0/DCSE OR 934033-0-0-0/DCSE OR 934047-0-0-0/DCSE OR
                934061-0-0-0/DCSE OR 934062-0-0-0/DCSE OR 934064-0-0-0/DCSE OR
                934065-0-0-0/DCSE OR 934073-0-0-0/DCSE OR 934074-0-0-0/DCSE OR
                934075-0-0-0/DCSE OR 934077-0-0-0/DCSE OR 934078-0-0-0/DCSE OR
                934079-0-0-0/DCSE OR 934080-0-0-0/DCSE OR 934081-0-0-0/DCSE OR
                934082-0-0-0/DCSE OR 934083-0-0-0/DCSE OR 934085-0-0-0/DCSE OR
                934106-0-0-0/DCSE OR 934110-0-0-0/DCSE OR 934112-0-0-0/DCSE OR
                934116-0-0-0/DCSE OR 934117-0-0-0/DCSE OR 934123-0-0-0/DCSE OR
                934134-0-0-0/DCSE OR 934151-0-0-0/DCSE OR 934154-0-0-0/DCSE OR
                934158-0-0-0/DCSE OR 934159-0-0-0/DCSE OR
                D SCAN

     FILE 'STNGUIDE' ENTERED AT 12:25:32 ON 30 MAY 2006

     FILE 'WPIX' ENTERED AT 12:26:09 ON 30 MAY 2006
L26            1 SEA ABB=ON  PLU=ON  L25 AND (C27 H33 I N4 O3)/MF
                D SCAN
                SELECT L26 1- DCSE
L27            1 SEA ABB=ON  PLU=ON  933801-0-0-0/KW
L28            0 SEA SSS SAM L14
                D QUE STAT
L29            1 SEA SSS FUL L14
L30            1 SEA ABB=ON  PLU=ON  L29/DCR
                SELECT L29 1- SDCN
L31            1 SEA ABB=ON  PLU=ON  RAEX6A/DCN
L32            1 SEA ABB=ON  PLU=ON  L27 OR L30 OR L31
                SAVE TEMP L32 GEM354WPI1/A

     FILE 'STNGUIDE' ENTERED AT 12:29:48 ON 30 MAY 2006

     FILE 'ZCAPLUS' ENTERED AT 12:30:08 ON 30 MAY 2006
L33            QUE ABB=ON  PLU=ON  BOYS, M?/AU
L34            QUE ABB=ON  PLU=ON  SCHRETZMAN, L?/AU
L35            QUE ABB=ON  PLU=ON  TOLLEFSON, M?/AU
L36            QUE ABB=ON  PLU=ON  CHANDRAKUMAR, N?/AU
L37            QUE ABB=ON  PLU=ON  KHANNA, I?/AU
L38            QUE ABB=ON  PLU=ON  NGUYEN, M?/AU
L39            QUE ABB=ON  PLU=ON  DOWNS, V?/AU
L40            QUE ABB=ON  PLU=ON  MOHLER, S?/AU
```

```
L41             QUE ABB=ON  PLU=ON  GESICKI, G?/AU
L42             QUE ABB=ON  PLU=ON  PENNING, T?/AU
L43             QUE ABB=ON  PLU=ON  CHEN, B?/AU
L44             QUE ABB=ON  PLU=ON  WANG, Y?/AU
L*** DEL        QUE KHILEVICH, A?/U
L45             QUE ABB=ON  PLU=ON  KHILEVICH, A?/AU
L46             QUE ABB=ON  PLU=ON  DESAI, B?/AU
L47             QUE ABB=ON  PLU=ON  YU, Y?/AU
L48             QUE ABB=ON  PLU=ON  WENDT, J?/AU
L49             QUE ABB=ON  PLU=ON  STENMARK, H?/AU
L50             QUE ABB=ON  PLU=ON  WU, H?/AU
L51             QUE ABB=ON  PLU=ON  HUFF, R?/AU
L52             QUE ABB=ON  PLU=ON  NAGARAJAN, S?/AU
L53             QUE ABB=ON  PLU=ON  DEVADAS, B?/AU
L54             QUE ABB=ON  PLU=ON  LU, H?/AU
L55             QUE ABB=ON  PLU=ON  RUSSEL, M?/AU
L56             QUE ABB=ON  PLU=ON  SPANGLER, D?/AU
L57             QUE ABB=ON  PLU=ON  PARIKH, M?/AU
L58             QUE ABB=ON  PLU=ON  PHARMACIA/PA,CS,SO

     FILE 'STNGUIDE' ENTERED AT 12:34:29 ON 30 MAY 2006

     FILE 'HCAPLUS, MEDLINE, BIOSIS, PASCAL, JICST-EPLUS, CABA, LIFESCI,
     DRUGU, DRUGB, VETU, VETB, WPIX, SCISEARCH, CONF, CONFSCI, DISSABS'
     ENTERED AT 12:37:36 ON 30 MAY 2006
L59         194315 SEA ABB=ON  PLU=ON  (L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR
                   L39 OR L40 OR L41 OR L42 OR L43 OR L44 OR L45 OR L46)
L60          83410 SEA ABB=ON  PLU=ON  (L47 OR L48 OR L49 OR L50 OR L51 OR L52 OR
                   L53 OR L54 OR L55 OR L56 OR L57)
L61            904 SEA ABB=ON  PLU=ON  (L59 OR L60) AND ?INTEGRIN?
L62          10520 SEA ABB=ON  PLU=ON  (L33 OR L34 OR L35 OR L36 OR L37) OR (L39
                   OR L40 OR L41 OR L42) OR (L45 OR L46) OR (L48 OR L49) OR (L51
                   OR L52 OR L53) OR (L55 OR L56 OR L57)
L63            215 SEA ABB=ON  PLU=ON  (L38 OR L43 OR L44 OR L47 OR L50 OR L54)
                   AND L58
L64             94 SEA ABB=ON  PLU=ON  (L62 OR L63) AND ?INTEGRIN?
L65             85 SEA ABB=ON  PLU=ON  L64 AND (?INTEGRIN?(L)(?ANTAGON? OR
                   ?INHIBIT? OR ?PROHIBIT? OR ?BLOCK? OR STOP? OR DISRUPT? OR
                   INTERRUPT? OR CONTROL? OR MODERAT? OR MODULAT? OR ?REGULAT? OR
                   ?PREVENT? OR ?REDUC? OR ?IMPED? OR ?SUPPRESS? OR REPRESS? OR
                   RETARD? OR SLOW?))
L66             21 SEA ABB=ON  PLU=ON  L65 AND (ALKANOIC? OR HETEROALKANOIC? OR
                   ?BUTANOIC?)
L67             11 DUP REM L66 (10 DUPLICATES REMOVED)
                        ANSWERS '1-9' FROM FILE HCAPLUS
                        ANSWERS '10-11' FROM FILE BIOSIS
                   SAVE TEMP L67 GEM354MULINV/A

     FILE 'STNGUIDE' ENTERED AT 12:57:16 ON 30 MAY 2006
                D SAVED
                D QUE STAT L16
                D QUE NOS L17
                D QUE NOS L24
                D QUE STAT L18
                D QUE STAT L20
                D QUE STAT L22
                D QUE STAT L32
                D QUE STAT L11

     FILE 'HCAPLUS, TOXCENTER, USPATFULL, WPIX' ENTERED AT 13:00:18 ON 30 MAY
```

2006

L68 2 DUP REM L11 L18 L20 L22 L32 (2 DUPLICATES REMOVED)
ANSWER '1' FROM FILE HCAPLUS
ANSWER '2' FROM FILE USPATFULL

FILE 'STNGUIDE' ENTERED AT 13:00:24 ON 30 MAY 2006

FILE 'HCAPLUS, USPATFULL' ENTERED AT 13:00:34 ON 30 MAY 2006
D IBIB ED AB IND HITSTR

FILE 'STNGUIDE' ENTERED AT 13:00:35 ON 30 MAY 2006

FILE 'HCAPLUS, USPATFULL' ENTERED AT 13:00:45 ON 30 MAY 2006
D IBIB AB HITSTR 2

FILE 'STNGUIDE' ENTERED AT 13:00:46 ON 30 MAY 2006
D QUE STAT L67

FILE 'HCAPLUS, BIOSIS' ENTERED AT 13:02:10 ON 30 MAY 2006
D IBIB ED AB L67 1-11

FILE 'STNGUIDE' ENTERED AT 13:02:12 ON 30 MAY 2006

FILE 'STNGUIDE' ENTERED AT 13:02:32 ON 30 MAY 2006

FILE HOME

FILE STNGUIDE
FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: May 26, 2006 (20060526/UP).

FILE ZCAPLUS

FILE COVERS 1907 - 30 May 2006 VOL 144 ISS 23
FILE LAST UPDATED: 29 May 2006 (20060529/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE HCAPLUS

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 May 2006 VOL 144 ISS 23
FILE LAST UPDATED: 29 May 2006 (20060529/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE WPIX
FILE LAST UPDATED: 26 MAY 2006 <20060526/UP>
MOST RECENT DERWENT UPDATE: 200634 <200634/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf <

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomson.com/support/patents/coverage/latestupdates/

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html and
http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf <<<

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 29 MAY 2006 HIGHEST RN 885947-35-3
DICTIONARY FILE UPDATES: 29 MAY 2006 HIGHEST RN 885947-35-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****************************************************************
*                                                               *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,   *
* effective March 20, 2005. A new display format, IDERL, is now     *
* available and contains the CA role and document type information. *
*                                                               *
*****************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

FILE TOXCENTER

FILE COVERS 1907 TO 30 May 2006 (20060530/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The MEDLINE file segment has been updated with 2006 MEDLINE data and features. See HELP RLOAD for details.

TOXCENTER thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.
See http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html
for a description of changes.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 30 May 2006 (20060530/PD)
FILE LAST UPDATED: 30 May 2006 (20060530/ED)
HIGHEST GRANTED PATENT NUMBER: US7055175
HIGHEST APPLICATION PUBLICATION NUMBER: US2006112473
CA INDEXING IS CURRENT THROUGH 30 May 2006 (20060530/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 30 May 2006 (20060530/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

FILE LREGISTRY
LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE BEILSTEIN
FILE LAST UPDATED ON MARCH 15, 2006

FILE COVERS 1771 TO 2006.
FILE CONTAINS 9,516,393 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search for a chemical name, a compounds with available reaction information by combining with PRE/FA, REA/FA or more generally with RX/FA. The BEILSTEIN Registry Number (BRN) is the link between a BEILSTEIN compound and belonging reactions. For mo detailed reaction searches BRNs can be searched as reaction partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE <<<

****
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST. *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS. *
* FOR PRICE INFORMATION SEE HELP COST *

****
NEW
* PATENT NUMBERS (PN) AND BABS ACCESSION NUMBERS (BABSAN) CAN NOW BE SEARCHED, SELECTED AND TRANSFERRED.
* NEW DISPLAY FORMATS ALLREF, ALLP AND BABSAN SHOW ALL REFERENCES, ALL PATENT REFERENCES, OR ALL BABS ACCESSION NUMBERS FOR A COMPOUND AT A GLANCE.

FILE CHEMINFORMRX
FILE LAST UPDATED: 8 MAR 2006 <20060308/UP>

>>> CAS Registry Numbers are available for substances prior to 1995 <<<

FILE MARPAT
FILE CONTENT: 1961-PRESENT VOL 144 ISS 22 (20060526/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US	2006062725	23 MAR 2006
DE	102004045029	16 MAR 2006
EP	1634887	15 MAR 2006
JP	2006073583	16 MAR 2006
WO	2006045852	04 MAY 2006
GB	2416167	18 JAN 2006
FR	2875804	31 MAR 2006
RU	2270725	27 FEB 2006
CA	2518664	10 MAR 2006

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

FILE MEDLINE
FILE LAST UPDATED: 27 MAY 2006 (20060527/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 24 May 2006 (20060524/ED)

FILE PASCAL
FILE LAST UPDATED: 29 MAY 2006 <20060529/UP>
FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
IN THE BASIC INDEX (/BI) FIELD <<<

FILE JICST-EPLUS
FILE COVERS 1985 TO 30 MAY 2006 (20060530/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED
TERM (/CT) THESAURUS RELOAD.

FILE CABA
FILE COVERS 1973 TO 3 May 2006 (20060503/ED)

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The CABA file was reloaded 7 December 2003. Enter HELP RLOAD for details.

FILE LIFESCI
FILE COVERS 1978 TO 12 May 2006 (20060512/ED)

FILE DRUGU
FILE LAST UPDATED: 29 MAY 2006 <20060529/UP>
>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<
>>> THESAURUS AVAILABLE IN /CT <<<

FILE DRUGB
>>> FILE COVERS 1964 TO 1982 - CLOSED FILE <<<

FILE VETU
FILE LAST UPDATED: 02 JAN 2002 <20020102/UP>
FILE COVERS 1983-2001

FILE VETB
FILE LAST UPDATED: 25 SEP 94 <940925/UP>
FILE COVERS 1968-1982

FILE SCISEARCH

FILE COVERS 1974 TO 25 May 2006 (20060525/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE CONF
FILE LAST UPDATED: 23 DEC 2005 <20051223/UP>
FILE COVERS 1976 TO 2005.

<<< CONF IS NO LONGER BEING UPDATED AS OF JANUARY 2006 >>>

FILE CONFSCI
FILE COVERS 1973 TO 10 Apr 2006 (20060410/ED)

CSA has resumed updates, see NEWS FILE

FILE DISSABS
FILE COVERS 1861 TO 25 MAY 2006 (20060525/ED)

=>